National Institutes of Health (NIH) Small Business Innovative Research (SBIR) Grant

The National Institutes of Health (NIH) has taken notice of the work we are doing at OmniLife. The NIH enthusiastically supports our mission to save lives by optimizing communication and information for organ transplantation. OmniLife has achieved national notoriety for our work by winning the Small Business Innovative Research Grant (SBIR) Phase I and II awards, totaling nearly $2M.

The OmniLife research team is led by health informatics expert and CTO, Eric Pahl, and the veteran cardiothoracic transplant surgeon and principal investigator, Dr. Bob Emery. They are joined by a prestigious group of innovative MDs and PhDs from leading clinical institutions across the continent.

  • Starzl Network for Excellence in Pediatric Transplantation (SNEPT)
    • UPMC, Dr. George Mazariegos
    • Mt. Sinai, Dr. John Bucuvalas
    • UCSF, Dr. Emily Perito
    • NYPresbyterian, Dr. Steven Lobritto
    • TorontoSickKids, Dr. Vicky Ng
    • UVA, Dr. Sarah Rasmussen
    • Emory, Dr. Rene Romeru
    • UPMC, Dr. James Squires
  • UMN, Dr. Bill Payne
  • Metrolina, Dr. Ben Hippen
  • Carolina’s Medical Center, Dr. Karl Welke
  • UCSF, Dr. Chris Freise
  • St. Jude Medical, Dr. Manny Villafana
  • Iowa, Dr. Dave Axelrod
  • Iowa, Dr. Alan Reed
  • Intermountain, Dr. Diane Alonso
  • Donor Network West, Sean Van Slyck
  • Iowa Donor Network, Suzanne Conrad

Phase II

In September 2019, OmniLife received notice of award for a $1.5M, 2-year study to expand the work accomplished in Phase I by including clinical decision support. The study was IRB approved and supported by clinical experts throughout North America.

  • 2R44LM012575-02, “Artificial intelligence-enabled, real-time communication software for optimizing clinical decision making during the allocation, procurement, and transplantation of donated organs”

The three aims of the awarded study are:

  • Aim 1: Develop machine learning models that predict transplant outcomes at the time of organ offer
  • Aim 2: Validate the statistical significance and clinical relevance of these models with a clinical committee
  • Aim 3: Implement the models into TXP Chat™ and deliver the predictions at the time of organ offer, randomized controlled trial.

The three aims of the modified study are:

  • Aim 1: Develop a clinical decision support (CDS) engine, interface with TXP Chat™, and connect to OmniLife data lake.
  • Aim 2: Deploy previously validated algorithms to CDS as predictive models for incoming organ offers.
  • Aim 3: Implement the CDS and TXP Chat™ to the point of care, randomized control trial.